Table 1. Inhibitory Activities of Compounds 12a–14a and 14c against A/WSN/33 (H1N1).
| compound | IC50 (μM)a | CC50 (μM)b | SIc |
|---|---|---|---|
| 12a | 4.69 ± 6.03 | >100 | >21.32 |
| 12b | 2.87 ± 2.37 | >100 | >34.84 |
| 12c | 0.31 ± 0.17 | >100 | >322.58 |
| 12d | 25.07 ± 1.05 | >100 | >3.99 |
| 12e | 0.57 ± 2.64 | >100 | >175.44 |
| 13a | 6.86 ± 0.58 | >100 | >14.58 |
| 13b | 31.58 ± 1.94 | >100 | >3.17 |
| 13c | 0.38 ± 0.28 | >100 | >263.16 |
| 13d | 0.23 ± 0.13 | >100 | >434.78 |
| 13e | NDd | >100 | – |
| 14a | 16.72 ± 0.75 | >100 | >5.98 |
| 14c | 9.84 ± 1.36 | >100 | >10.16 |
| OA | 72.27 ± 3.18 | >100 | >1.38 |
| OSV-pe | 1.82 ± 0.25 | >100 | >54.95 |
a
IC50 is the concentration required to inhibit viral-infection-induced CPE by 50%. Values are means of duplicate samples from three independent experiments.
b
CC50 is the concentration required to reduce the viability of normal, noninfected MDCK cells by 50%.
c
SI is the selectivity index, defined as CC50/IC50.
d
Not detectable.
e
Oseltamivir phosphate, the positive control.